A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease

Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review

“…From the 114 studies, full-text was unavailable for one study 13 , 2 studies were duplicates published under different titles 14,15 , one study only described the study design 16 and 6 studies did not report safety, tolerability and/or toxicity results 7,[17][18][19][20][21] . These together with 11 case reports [22][23][24][25][26][27][28][29][30][31][32] and 2 letters to the editor were excluded 33,34 . Ultimately, a total of 91 studies were included in the systemic safety review.…”

Analogue peptides for the immunotherapy of human acute myeloid leukemia

“…Similar modifications have led to peptide analogues which are effective at inducing immune responses against a range of tumor types including leukemia and solid tumors [54, [57][58][59]94,95](reviewed in [96]). Despite inherent problems in demonstrating the ability of modified peptides to recognize and kill tumor cells, some heteroclitic epitopes have shown promise in phase I clinical trials [18,71,97]. Future studies will increasingly focus on mutated peptides that provide a cancer specific target for immunotherapy and the examination of overlapping peptide pools [98] to determine natural epitopes, that often exist at low frequencies, for future targeting.…”

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

“…[9][10][11][12] We previously reported the feasibility of vaccinating patients with native as well as heteroclitic peptides for bcr-abl. [13][14][15] We have now adapted a similar strategy in modifying WT1 peptides. Computer prediction analysis has allowed us to design several synthetic peptides capable of stabilizing major histocompatibility complex class I A0201 molecules better than native sequences and also able to elicit WT1-specific cytotoxic T-cell lymphocytes more effectively than native sequences.…”